綜述文章 - 細胞激素誘導殺手細胞（CIK）療法：一種有前景的腎細胞癌和攝護腺癌免疫治療策略

蔣智宏、李宜達¹、洪健華²、黃昭淵²

臺北市立聯合醫院中興院區/林森中醫昆明院區 外科部泌尿外科；¹臺北醫學大學牙醫學院，²臺灣大學附設醫院 泌尿部

Review Article - Cytokine-Induced Killer (CIK) Cell Therapy：A Promising Immunotherapeutic Strategy for Renal Cell Carcinoma and Prostate Cancer

Chih-Hung Chiang、I-Ta Lee¹、Jian-Hua Hong²、Chao-Yuan Huang²

Division of Urology, Department of Surgery, Taipei City Hospital, Zhongxing Branch and Linsen Chinese Medicine and Kunming Branch, Taipei 103212, Taiwan；¹School of Dentistry, College of Oral Medicine, Taipei Medical University, Taipei, 110301, Taiwan；²Department of Urology, National Taiwan University Hospital, Taipei 100229, Taiwan

     Renal cell carcinoma (RCC) and Prostate cancer (PCa) are challenging genitourinary malignancies, especially in advanced stages. Although current standard treatments—such as TKIs/ICIs for metastatic RCC and ADT combined with ARPIs for PCa—have improved survival, therapeutic resistance, recurrence, and toxicity continue to compromise long-term outcomes. Consequently, innovative immunotherapies are urgently needed to strengthen anti-tumor immunity and enhance survival.

     Cytokine-Induced Killer (CIK) cell therapy has emerged as a promising adoptive immunotherapy. CIK cells are a heterogeneous population of potent immune effectors, notably including NK-like T cells (CD3⁺CD56⁺). Their critical advantage is their ability to exert MHC-unrestricted cytotoxic activity against a broad range of tumor types, primarily mediated through NKG2D receptor-ligand interactions.

     Beyond their simple preparation, robust proliferation, and low cost, CIK cells offer significant clinical benefits, including reduced relapse rates, improved quality of life, prolonged survival, and favorable safety/tolerability profiles. Furthermore, the versatility of CIK cells allows for seamless integration with existing targeted and immunotherapeutic regimens.

     This review highlights recent advances in CIK cell therapy for RCC and PCa, emphasizing their underlying biological mechanisms, preclinical and clinical evidence, and future perspectives for clinical translation and combination immunotherapy.